Compare Expensify Inc (EXFY) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Heron Therapeutics Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Expensify Inc is far larger — about 3.1× Heron Therapeutics Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Heron Therapeutics Inc for 35 Days on average.
| EXFY | HRTX | |
|---|---|---|
Market Cap | $208.82M | $68.01M |
Volume | 456,102 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $2.72 | $1.49 |
52-Week Low | $0.75 | $0.27 |
Typical Hold Time | 41 Days | 35 Days |
Enterprise Value | $148.44M | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.30, up 1.32% with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 and Q2 2026 earnings beats and positive operating cash flow of $20.09M in 2025. Recent business developments include AI-native ERP integrations and European card expansion, signaling growth initiatives. However, the stock carries a high P/E ratio of 258.82 and negative profitability metrics, presenting a mixed investment case.
The outlook remains cautiously optimistic with analyst consensus pointing to significant upside (target $13.75), but investors face risks from persistent net losses and competitive pressures. The key opportunity lies in the company's strategic pivot to AI-driven solutions and international expansion, though execution risks and valuation concerns warrant careful monitoring.
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
